Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. (SYRS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SYRS · as of Jun 30, 2025
Ownership Breakdown
1
Institutional Holders
▼ 3 vs Q1
$3
Total Inst. Value
▼ $12,372 vs Q1
26.83M
Shares Outstanding
freeFloat 99.94%
113
13F Shares Held
▼ 462,841 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SYRS largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 5 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 113 | 0.03% | 0.03% | $24,000 | Aug 13, 2025 | ▲ 113 |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 7, 2025 | EXIT |
BAADER BANK AKTIENGESELLSCHAFT pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Jul 10, 2025 | EXIT |
1492 CAPITAL MANAGEMENT LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 13, 2025 | EXIT |
XTX TOPCO LTD pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 12, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
1
Increased
+113 shares0
New Positions
first time holders0
Decreased
−0 shares4
Sold Out
fully exitedNet shares change (top 50)
+113
+113 / −0
Net new holders
-3
0 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SYRS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
5
Buy transactions
16
Sell transactions
0.31
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Simonian Nancy A director | Dec 2, 2024 | Sale | 37,070 | $0.27 | $10.0K | 4.0K | Form 4 ↗ |
Simonian Nancy A director | Nov 25, 2024 | Sale | 134,713 | $0.27 | $35.7K | 41.1K | Form 4 ↗ |
Stephens Kristin Chief Development Officer | Nov 18, 2024 | Sale | 36,133 | $0.22 | $7.9K | 0 | Form 4 ↗ |
Roth David Chief Medical Officer | Nov 18, 2024 | Sale | 12,099 | $0.20 | $2.4K | 0 | Form 4 ↗ |
Quirk Gerald E Chief Legal & Compliance Offic | Nov 19, 2024 | Sale | 46,657 | $0.22 | $10.3K | 0 | Form 4 ↗ |
Chee Conley President & CEO | Nov 18, 2024 | Sale | 134,797 | $0.20 | $26.9K | 0 | Form 4 ↗ |
Haas Jason Chief Financial Officer | Nov 18, 2024 | Sale | 137,803 | $0.21 | $29.0K | 0 | Form 4 ↗ |
Roth David Chief Medical Officer | Oct 31, 2024 | Tax Withhold | 6,776 | $2.09 | $14.2K | 12.1K | Form 4 ↗ |
Haas Jason Chief Financial Officer | Oct 31, 2024 | Tax Withhold | 5,624 | $2.09 | $11.8K | 137.8K | Form 4 ↗ |
Chee Conley President & CEO | Oct 31, 2024 | Tax Withhold | 8,707 | $2.09 | $18.2K | 130.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Syros Pharmaceuticals, Inc. (SYRS) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 0.06%, while retail and public investors account for the remaining 99.94%.
The largest institutional shareholder of Syros Pharmaceuticals, Inc. is ADVISOR GROUP HOLDINGS, INC., holding approximately 113 shares — equal to 0.03% of outstanding shares — as of June 30, 2025.
A total of 1 institutional investors currently hold SYRS stock, with a combined institutional value of approximately $3 as of the most recent 13F filing period.
Frequently asked questions
SYRS ownershipSyros Pharmaceuticals, Inc. (SYRS) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is ADVISOR GROUP HOLDINGS, INC. with a 0.03% stake. Company insiders hold 0.06%. Data sourced from SEC Form 13F as of June 30, 2025.